Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer

Summary

The purpose of this study is to evaluate the efficacy of Udenafil (Zydena®, Dong-A Pharmaceutical co., Ltd, Seoul, Korea) in treatment of erectile dysfunction after radical resection for sigmoid colon and rectal cancer. In this study, the efficacy of Udenafil will be evaluated in treatment for patient with chronic erectile dysfunction, which developed after radical resection for sigmoid and rectal cancer and continues 12 months after the surgery.

Timeline

Start

2009-03

Primary completion

2012-01

Completion

2012-01

Drugs

Indications